ELVN ▼ -6.8% - Enliven Therapeutics, Inc.
$ELVN ELVN - Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia
06-OCT-2026 04:08 PM ET
Share this post
More filings for $ELVN
ELVN ▲ +0.9% - Enliven Therapeutics, Inc.Oct 2, 2026ELVN ▲ +1.1% - Enliven Therapeutics, Inc.Sep 3, 2026ELVN ▲ +0.1% - Enliven Therapeutics, Inc.Aug 31, 2026ELVN - Enliven Therapeutics, Inc. - SEC Filing Update (06-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 6, 2026$ELVN SEC Filing Update (24-JUN-2026) | ThinkSabio - Stocks SimplifiedJun 24, 2026$ELVN SEC Filing Update (22-JUN-2026) | ThinkSabio - Stocks SimplifiedJun 22, 2026
View full $ELVN filing history →💬 Comments
Loading comments…
Leave a comment